
Happiness Biotech Group Limited HAPP
Quarterly report 2026-Q2
added 05-12-2026
Happiness Biotech Group Limited Long Term Debt Current 2011-2026 | HAPP
Annual Long Term Debt Current Happiness Biotech Group Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 102 K | 102 K | 102 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Coherus BioSciences
CHRS
|
1.83 M | $ 1.63 | -4.4 % | $ 191 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
4.21 M | $ 7.83 | -5.21 % | $ 214 M | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.12 | - | $ 649 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M | ||
|
Exelixis
EXEL
|
27.9 M | $ 51.1 | -0.37 % | $ 13.9 B | ||
|
Forte Biosciences
FBRX
|
416 K | $ 23.96 | -2.84 % | $ 310 M | ||
|
Galera Therapeutics
GRTX
|
133 K | - | -32.59 % | $ 7.61 M | ||
|
Karyopharm Therapeutics
KPTI
|
969 K | $ 8.9 | 0.56 % | $ 1.08 M | ||
|
AbCellera Biologics
ABCL
|
5.82 M | $ 4.4 | -7.76 % | $ 1.31 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 17.3 | -5.57 % | $ 809 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 91.99 | -0.26 % | $ 22.2 B | ||
|
Compugen Ltd.
CGEN
|
768 K | $ 3.03 | 6.32 % | $ 283 M | ||
|
Gilead Sciences
GILD
|
102 M | $ 132.06 | -0.74 % | $ 164 B | ||
|
Genmab A/S
GMAB
|
26 M | $ 26.9 | 1.32 % | $ 1.74 B | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
56 K | $ 3.49 | -4.12 % | $ 5.75 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Grifols, S.A.
GRFS
|
117 M | $ 7.79 | 1.04 % | $ 5.29 B | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Fortress Biotech
FBIO
|
2.13 M | $ 2.3 | 3.14 % | $ 64.2 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 21.57 | -0.55 % | $ 2.74 B | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
Fennec Pharmaceuticals
FENC
|
2 K | $ 9.24 | 36.48 % | $ 264 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K |